This is similar to the standard incidence rate for SPM observed following treatment with fludarabine-cyclophosphamide-rituximab (2.4) and in a large cohort of CLL patients followed prior to the availability of BTK inhibitors (2.2) [110,111]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.